UY27688A1 - Administración de agentes para el tratamiento de la inflamación . - Google Patents

Administración de agentes para el tratamiento de la inflamación .

Info

Publication number
UY27688A1
UY27688A1 UY27688A UY27688A UY27688A1 UY 27688 A1 UY27688 A1 UY 27688A1 UY 27688 A UY27688 A UY 27688A UY 27688 A UY27688 A UY 27688A UY 27688 A1 UY27688 A1 UY 27688A1
Authority
UY
Uruguay
Prior art keywords
administration
inflammation
agents
treatment
agent
Prior art date
Application number
UY27688A
Other languages
English (en)
Inventor
Julie Taylor
Ted A Yednock
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of UY27688A1 publication Critical patent/UY27688A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para reducir crónicamente una inflamación patológica de un paciente mediante la administración de un agente que se enlaza específicamente a un alfa-4 integrin o bien, se revela un dimer (reductor) que comprende un alfa-4 integrin. El agente proporcionado debe tener una afinidad aglutinante de modo que la administración sea suficiente para suprimir la inflamación patológica, y el agente sea administrado crónicamente para la supresión a largo plazo de la inflamación patológica.
UY27688A 2002-04-23 2003-02-27 Administración de agentes para el tratamiento de la inflamación . UY27688A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37450102P 2002-04-23 2002-04-23

Publications (1)

Publication Number Publication Date
UY27688A1 true UY27688A1 (es) 2003-10-31

Family

ID=38813807

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27688A UY27688A1 (es) 2002-04-23 2003-02-27 Administración de agentes para el tratamiento de la inflamación .

Country Status (2)

Country Link
PE (1) PE20040204A1 (es)
UY (1) UY27688A1 (es)

Also Published As

Publication number Publication date
PE20040204A1 (es) 2004-04-08

Similar Documents

Publication Publication Date Title
PL372306A1 (en) Administration of agents for the treatment of inflammation
BR0315700A (pt) Dispositivo médico implantável que incorpora rapamicina deuterada para a aplicação controlada da mesma
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
DK1267897T3 (da) Behandling af kongestiv hjerteinsuffiens med forbehandlet autologt blod
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
AR109263A2 (es) Composición que comprende moxidectina
BRPI0406499A (pt) Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
BR9906813A (pt) Método para administração de insulina aspb28- humana
EA200101089A1 (ru) Новый способ лечения
EA200500859A1 (ru) Хинолинилпирролопиразолы
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
UY27688A1 (es) Administración de agentes para el tratamiento de la inflamación .
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
ATE383863T1 (de) Kombinationschemotherapie
BRPI0414518A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano
MXPA03006477A (es) Metodo de tratamiento de diabetes tipo i.
BR9809376A (pt) Pregnan-3-ol-20-onas
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
FI20010233A0 (fi) Menetelmä sydämen vajaatoiminnan hoitoon
ES2193285T3 (es) Inhibidor de oxido nitrico (no)-sintasa para prevenir la diabetes de tipo ii.
BR0312333A (pt) Terapia de combinação e agente para sua execução

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126